3 Contract Drug Development Company, Isobutylene Derivatives Maker and Global Branded Generics Company Stocks With a Strong Future Roadmap: Anthem Biosciences, Vinati Organics and Lupin
- November 2, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Anthem Biosciences, Vinati Organics and Lupin: ROE of 14.0% to 23.8% and FY22 to FY26 revenue CAGR of 8.0% to 15.5%. Prices as of 30 Oct 2026.
Quick Answer
The three contract drug, chemical and generic stocks to watch are Anthem Biosciences, Vinati Organics and Lupin. Their return on equity ranges from 14.0% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 15.5%. Lupin has the highest return on equity at 23.8%, while Anthem Biosciences has the fastest revenue growth at 15.5% a year. Prices are based on the 30 October 2026 close, and this article is educational, not investment advice.
Contract drug, chemical and generic stocks offer a focused view of a sector where demand keeps widening. Anthem Biosciences, Vinati Organics and Lupin cover a contract drug development company, an isobutylene derivatives maker and a global branded generics company.
This list covers three contract drug, chemical and generic stocks with complete current figures: Anthem Biosciences, Vinati Organics and Lupin. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Contract Drug, Chemical and Generic Stocks?
Contract drug, chemical and generic stocks are listed companies that develop and manufacture drugs for global pharma and biotech firms, make isobutylene derivatives and other specialty chemicals, and sell branded generics in India and overseas. Their earnings depend on orders, export demand and product mix.
Contract Drug, Chemical and Generic Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 828.8 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
| Vinati Organics | 992.2 | 11,582 | 25.8 | 35.1 | 14.0 | 0.00 |
| Lupin | 2,011 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
On valuation, Vinati Organics and Lupin trade at a P/E below the industry P/E, while Anthem Biosciences trades above it, which reflects the growth the market already expects. Readers comparing contract drug, chemical and generic stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Contract Drug, Chemical and Generic Stocks Have a Strong Roadmap in India?
Contract drug, chemical and generic stocks have a strong roadmap in India because drug makers outsourcing more work, niche chemistry leadership and steady demand for medicines keep widening the market for these pharma and chemical companies.
- Outsourcing. Global pharma partners with Indian developers.
- Niche chemistry. Leading products support pricing strength.
- Branded generics. Repeat prescriptions support earnings.
Why Anthem Biosciences Features Among These Contract Drug, Chemical and Generic Stocks
Among the contract drug, chemical and generic stocks on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Why Vinati Organics Features Among These Contract Drug, Chemical and Generic Stocks
Among the pharma and chemistry exporters shares on this list, Vinati Organics is a specialty chemicals company and the world’s leading maker of isobutylene derivatives such as IBB and ATBS, which are used in pharma, polymers and oilfield applications.
In the June 2026 quarter, revenue grew 28.3% year on year to Rs 705 crore, while net profit rose 4.5% to Rs 109 crore. Revenue rose from Rs 1,676 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 8.0%.
Net profit grew from Rs 347 crore in FY22 to Rs 444 crore in FY26, which works out to a compound annual growth rate of 6.4%. The company has a return on equity of 14.0%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 11,582 crore. The stock trades at a P/E of 25.8, below the industry P/E of 35.1.
Roadmap: The company holds a leading global position in its core products, and has been developing new chemistries that serve several industries. A strong balance sheet with no debt supports its capacity expansion programme.
What to watch: Monitor demand for ATBS and the ramp-up of new products and capacity.
Why Lupin Features Among These Contract Drug, Chemical and Generic Stocks
Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Anthem Biosciences vs Vinati Organics vs Lupin on Key Financials
The table below sets the three contract drug, chemical and generic stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
| Vinati Organics | 1,676 | 2,280 | 8.0% | 444 | 19.5% |
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with contract drug, chemical and generic stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Contract Drug, Chemical and Generic Stocks
Every theme carries risks that deserve a check before any decision. For these contract drug, chemical and generic stocks, the main points are: Long-term pharma and chemistry exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter contract drug, chemical and generic stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Contract Drug, Chemical and Generic Stocks
Contract drug, chemical and generic stocks reward patient research into demand, execution and financial strength. Anthem Biosciences, Vinati Organics and Lupin each have a clear plan to grow. Based on the 30 October 2026 close, Anthem Biosciences trades at Rs 828.8, Vinati Organics at Rs 992.2 and Lupin at Rs 2,011. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these contract drug, chemical and generic stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track contract drug, chemical and generic stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are contract drug, chemical and generic stocks?
Ans. Contract drug, chemical and generic stocks are listed companies that develop and manufacture drugs for global pharma and biotech firms, make isobutylene derivatives and other specialty chemicals, and sell branded generics in India and overseas. Their earnings depend on orders, export demand and product mix. This list looks at three of them, Anthem Biosciences, Vinati Organics and Lupin, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.
Which contract drug, chemical and generic stocks are covered in this list?
Ans. This list covers Anthem Biosciences, Vinati Organics and Lupin. Based on the 30 October 2026 close, Anthem Biosciences traded at Rs 828.8, Vinati Organics at Rs 992.2 and Lupin at Rs 2,011. Their return on equity ranges from 14.0% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 15.5%.
Why do contract drug, chemical and generic stocks have a strong future roadmap in India?
Ans. Contract drug, chemical and generic stocks have a strong roadmap in India because drug makers outsourcing more work, niche chemistry leadership and steady demand for medicines keep widening the market for these pharma and chemical companies. The main drivers are as follows. Outsourcing. Global pharma partners with Indian developers. Niche chemistry. Leading products support pricing strength. Branded generics. Repeat prescriptions support earnings. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
How has Vinati Organics performed financially?
Ans. Revenue rose from Rs 1,676 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 8.0%. Net profit grew from Rs 347 crore in FY22 to Rs 444 crore in FY26, which works out to a compound annual growth rate of 6.4%. In the June 2026 quarter, revenue grew 28.3% year on year to Rs 705 crore, while net profit rose 4.5% to Rs 109 crore. The company has a return on equity of 14.0%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 11,582 crore. The stock trades at a P/E of 25.8, below the industry P/E of 35.1. Looking ahead, the company holds a leading global position in its core products, and has been developing new chemistries that serve several industries. A strong balance sheet with no debt supports its capacity expansion programme.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What risks should investors check before buying contract drug, chemical and generic stocks?
Ans. Investors should check a few risks before buying contract drug, chemical and generic stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of contract drug, chemical and generic stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.